You are here: Industry Insights > Parkinson's disease

News List

Treatment for Parkinson's OFF Periods: Istradefylline David Orchard-Webb
July 01, 2024
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the brain.One promising treatment for managing these off periods is Istradefylline, an adenosine A2A receptor antagonist.
Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's Disease prnasia
January 29, 2022
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases...
MapLight Therapeutics Receives Grant for Parkinson's Disease Research americanpharmaceuticalreview
December 16, 2020
MapLight Therapeutics announced a $8.1 million grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF), to undertake a large-scale, systematic investigation of the brain circuits and mechanisms that are responsible for triggering ...
Seelos Announces Patent for SLS-007 americanpharmaceuticalreview
November 02, 2020
Seelos Therapeutics has been issued U.S. patent number 10815271 (application number 16/311,593) from the United States Patent and Trademark Office (USPTO) covering the composition of matter for SLS-007.
Seelos Announces Initiation of Preclinical Study of SLS-007 in Parkinson's Disease americanpharmaceuticalreview
July 03, 2020
Seelos Therapeutics announced the initiation of a preclinical study of SLS-007 in Parkinson's disease (PD) delivered through an adeno associated viral (AAV) vector targeting the non-amyloid component core (NACore) of alpha synuclein (α-synuclein).
New treatment offers potentially promising results for the possibility of slowing, stopping, or even reversing Parkinson's disease worldpharmanews
March 06, 2019
A pioneering clinical trials program that delivered an experimental treatment directly to the brain offers hope that it may be possible to restore the cells damaged in Parkinson's disease.
Good News, Bad News on Levodopa for Parkinson's Disease drugs
January 24, 2019
The most potent drug available for Parkinson's disease, levodopa, treats symptoms of the disease but does nothing to either ease or increase its still-mysterious underlying causes, a new clinical trial has concluded.....
New Parkinson's disease drug target revealed through study of fatty acids worldpharmanews
December 06, 2018
Investigators studying Parkinson's disease (PD) have become increasingly interested in lipids since both molecular and genetic studies have pointed to the disruption of the balance of the brain's lipids as a potentially critical contributor to this diseas
Alkahest Doses First Subject in Phase 2 GRF6021 Trial americanpharmaceuticalreview
December 05, 2018
Alkahest announced dosing of the first subject in a Phase 2 clinical trial of its proprietary human plasma fraction, GRF6021, for the treatment of Parkinson's disease with associated mild cognitive impairment or dementia....
Newly discovered link between the appendix and Parkinson’s disease could point to the way to treatments fiercebiotech
November 02, 2018
Scientists led by the Van Andel Research Institute in Michigan scoured two large patient registries, encompassing data from 1.7 million people, and made an astounding ...

Previous page 1 2 3 Next page